Kailera Therapeutics (KLRA) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T17:02:54.870Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:02:54.870Z.

Quote observation: 2026-10-06T17:00:45.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: N/A
Quote market capitalization: 1,394,747,857
Total debt · period ending 2026-06-30: 10,216,000
Cash · period ending 2026-06-30: 130,300,999

FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

KLRA EBITDA Yield Metrics

EBITDA YIELD

N/A

KLRA Competitors' EBITDA Yield

KLRA

Kailera Therapeutics, Inc.

Current

Market Cap

$1.39B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBX

Inhibrx Biosciences Inc.

vs KLRA

Market Cap

$1.39B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PNTG

The Pennant Group, Inc.

vs KLRA

Market Cap

$1.42B

EBITDA Yield

3.89%

TTM Avg

3.95%

3Y Avg

3.70%

5Y Avg

2.96%

ANAB

AnaptysBio, Inc.

vs KLRA

Market Cap

$1.42B

EBITDA Yield

8.75%

TTM Avg

3.11%

3Y Avg

3.11%

5Y Avg

3.25%

BRVE

Braveheart Bio, Inc.

vs KLRA

Market Cap

$1.45B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

RARE

Ultragenyx Pharmaceutical Inc.

vs KLRA

Market Cap

$1.44B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MAZE

Maze Therapeutics, Inc.

vs KLRA

Market Cap

$1.44B

EBITDA Yield

N/A

TTM Avg

19.73%

3Y Avg

19.73%

5Y Avg

19.73%

OMER

Omeros Corporation

vs KLRA

Market Cap

$1.35B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs KLRA

Market Cap

$1.34B

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCSG

Healthcare Services Group, Inc.

vs KLRA

Market Cap

$1.46B

EBITDA Yield

11.13%

TTM Avg

6.15%

3Y Avg

7.10%

5Y Avg

6.61%

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Kailera Therapeutics, Inc. (KLRA)	$1.39B	N/A	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.39B	N/A	N/A	N/A	N/A
The Pennant Group, Inc. (PNTG)vs ›	$1.42B	3.89%	3.95%	3.70%	2.96%
AnaptysBio, Inc. (ANAB)vs ›	$1.42B	8.75%	3.11%	3.11%	3.25%
Braveheart Bio, Inc. (BRVE)vs ›	$1.45B	N/A	N/A	N/A	N/A
Ultragenyx Pharmaceutical Inc. (RARE)vs ›	$1.44B	N/A	N/A	N/A	N/A
Maze Therapeutics, Inc. (MAZE)vs ›	$1.44B	N/A	19.73%	19.73%	19.73%
Omeros Corporation (OMER)vs ›	$1.35B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.34B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.46B	11.13%	6.15%	7.10%	6.61%

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

KLRA EBITDA Yield Metrics

KLRA Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics